237 related articles for article (PubMed ID: 36527460)
1. Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis.
Cioccio J; Rakszawski K; Zheng H; Nickolich M; Naik S; Wirk B; Rybka W; Ehmann C; Silar B; Vajdic C; Shah N; Tuanquin L; Greiner R; Brown V; Hohl R; Claxton D; Mineishi S; Minagawa K; Shike H
Ann Hematol; 2023 Mar; 102(3):613-620. PubMed ID: 36527460
[TBL] [Abstract][Full Text] [Related]
2. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
3. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E; Labopin M; Labussière H; Fossard G; Chevallier P; Guillaume T; Yakoub-Agha I; Srour M; Bulabois CE; Huynh A; Chantepie S; Menard AL; Rubio MT; Ceballos P; Dulery R; Furst S; Malard F; Blaise D; Mohty M
Blood Cancer J; 2024 Feb; 14(1):31. PubMed ID: 38374026
[TBL] [Abstract][Full Text] [Related]
5. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
6. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
[TBL] [Abstract][Full Text] [Related]
7. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G; Gras L; Koster L; Kulagin A; Byrne J; Apperley JF; Halaburda K; Blau IW; Clark A; Kröger N; Griskevicius L; Carlson K; Collin M; Bloor A; Raiola AM; Blaise D; Aljurf M; López-Corral L; Sakellari I; Beguin Y; Wrobel T; de Rosa L; de Lavallade H; Hayden PJ; McLornan D; Chalandon Y; Yakoub-Agha I
Transplant Cell Ther; 2024 Jan; 30(1):93.e1-93.e12. PubMed ID: 37783337
[TBL] [Abstract][Full Text] [Related]
10. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
11. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
12. [Peripheral blood stem cell transplantation from HLA-mismatched unrelated donor or haploidentical donor for the treatment of X-linked agammaglobulinemia].
Nie L; Su T; Yang KT; Zhao L; Hu J; Yang SH; Xu YJ; Fu B
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Aug; 22(8):821-827. PubMed ID: 32800027
[TBL] [Abstract][Full Text] [Related]
13. Posttransplant cyclophosphamide beyond haploidentical transplantation.
Arcuri LJ; Ribeiro AAF; Hamerschlak N; Kerbauy MN
Ann Hematol; 2024 May; 103(5):1483-1491. PubMed ID: 37261557
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari L; Balaguer-Roselló A; Montoro J; Greco R; Hernani R; Lupo-Stanghellini MT; Villalba M; Giglio F; Facal A; Lorentino F; Guerreiro M; Bruno A; Pérez A; Xue E; Clerici D; Piemontese S; Piñana JL; Sanz MÁ; Solano C; de la Rubia J; Ciceri F; Peccatori J; Sanz J
Bone Marrow Transplant; 2022 Sep; 57(9):1389-1398. PubMed ID: 35680995
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
[TBL] [Abstract][Full Text] [Related]
16. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Modi D; Kondrat K; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
Transplant Cell Ther; 2021 Sep; 27(9):760-767. PubMed ID: 34174469
[TBL] [Abstract][Full Text] [Related]
19. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
20. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]